We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a ... Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. Show more
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 500,220 shares of Geron...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive...
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 261,000 shares of Geron...
U.S. commercial launch of RYTELOโข (imetelstat) began in June 2024 for patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who are relapsed/refractory to...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -4.01691331924 | 4.73 | 4.825 | 4.2301 | 10951587 | 4.53752415 | CS |
4 | -0.02 | -0.438596491228 | 4.56 | 4.825 | 4.21 | 8930722 | 4.49500998 | CS |
12 | 0.22 | 5.09259259259 | 4.32 | 5.06 | 4.15 | 9101531 | 4.57582544 | CS |
26 | 1.23 | 37.1601208459 | 3.31 | 5.34 | 3.05 | 10413980 | 4.27635073 | CS |
52 | 2.34 | 106.363636364 | 2.2 | 5.34 | 1.64 | 9343420 | 3.38990511 | CS |
156 | 3.17 | 231.386861314 | 1.37 | 5.34 | 0.9899 | 6009411 | 2.91934624 | CS |
260 | 3.23 | 246.564885496 | 1.31 | 5.34 | 0.75 | 4875545 | 2.58980482 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions